U.S. FDA staff raises concerns on Spectrum Pharma's cancer drug
20/09/2022 14:31
Sept 20 (Reuters) - The U.S. Food and Drug Administration's
(FDA) staff raised concerns over the safety of Spectrum
Pharmaceutical's SPPI.O experimental cancer drug and
questioned the benefits it provided over existing therapies,
dragging its shares 32% in premarket trade.
The staff's concerns over poziotinib were raised in the
regulator's briefing documents ahead of a meeting of its
external advisers on Thursday.
(Reporting by Leroy Leo in Bengaluru; editing by Uttaresh.V)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary